630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Harmony Biosciences Holds 2026 Annual Meeting; Director Elections Conducted
Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
APPOINTS Glenn Reicin as Chief Financial Officer
Annual Report to Security Holders
Strengthens Executive Team with NEW Appointment and ANNOUNCES Additions TO ITS bOARD
Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATION
Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Prospectus filed pursuant to Rule 424(b)(7)